Show simple item record

Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer

dc.contributor.authorVatansever, Sezai
dc.contributor.authorAk, Naziye
dc.date.accessioned2021-03-02T15:38:51Z
dc.date.available2021-03-02T15:38:51Z
dc.identifier.citationAk N., Vatansever S., "Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer", JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021
dc.identifier.issn0269-4727
dc.identifier.othervv_1032021
dc.identifier.otherav_34f9388a-47aa-443c-9cea-6a83df13b270
dc.identifier.urihttp://hdl.handle.net/20.500.12627/1591
dc.identifier.urihttps://doi.org/10.1111/jcpt.13364
dc.description.abstractWhat is known and objective: Patients with ovarian cancer have not benefited substantially from immunotherapy. We report a case of ovarian cancer, however, that responded well to the programmed cell death-ligand 1 inhibitor atezolizumab.
dc.language.isoeng
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectPharmacology
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectHealth Sciences
dc.subjectLife Sciences
dc.subjectDrug Guides
dc.subjectPharmacy
dc.subjectPharmacology (medical)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectSağlık Bilimleri
dc.subjectEczacılık
dc.titleDramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.contributor.firstauthorID2512637


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record